In a post hoc analysis of the same trial, patients treated with nivolumab, as compared to those who received a placebo, seemed to show numerically improved PFS in the case of the positive tumor PD-L1 CPS (≥1%) and a low NLR at baseline, while no improvement was observed in patients with negative PD-L1 CPS (<1%) and a high baseline NLR [118]. The gene discussed is CD274; the disease is neoplasm.